Citations of this article
Mendeley users who have this article in their library.
Get full text


Daclizumab is an interleukin-2 receptor antagonist which is used for induction therapy in heart transplant patients. It has few side effects and is associated with a low infection rate. Postoperative renal failure after heart transplantation is common and potentially fatal. The administration of calcineurin inhibitors in the postoperative period can aggravate the situation. We report the cases of six patients who underwent heart transplantation and developed acute renal failure in the immediate postoperative period. All were administered daclizumab weekly to avoid the introduction of calcineurin inhibitors and to facilitate recovery of renal function. Calcineurin inhibitors were introduced only once renal function had improved. Renal function recovered in all cases and there was a low complication rate. The administration of repeated doses of daclizumab to patients who experience acute postoperative renal failure after heart transplantation may provide an alternative therapeutic approach that enables calcineurin inhibitors to be avoided and, consequently, renal function to recover. © 2010 Sociedad Española de Cardiología. Published by Elsevier España, S.L. All rights reserved.




Sánchez Lázaro, I. J., Almenar Bonet, L., Martínez Dolz, L., Buendía Fuentes, F., Navarro Manchón, J., Agüero Ramón-Llin, J., … Salvador Sanz, A. (2011). Dosis repetidas de daclizumab para retrasar la instauración del inhibidor de la calcineurina en pacientes con trasplante cardiaco y disfunción renal postoperatoria. Revista Espanola de Cardiologia, 64(3), 237–239. https://doi.org/10.1016/j.recesp.2010.05.001

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free